DUBLIN--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of CV Ingenuity. Financial terms of the transaction were not disclosed. CV Ingenuity’s core technology, still in the investigational phase, is a Drug Coated Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release system. “We are pleased to add both the talented team members at CV Ingenuity as well as their promising DCB technology to our growing portfolio of vascular products,” said Stacy Enxing Seng, President, Vascular Therapies, Covidien. “We are committed to being the clear first choice for our physician and hospital partners by delivering technology to improve patient outcomes.”
